GlassScriptPhysician profile
Andrew D Chung
NPI 1962500413
$10,551.22
in general payments reported to CMS, 2019-2025
55 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,460 · 2020: $1,797 · 2021: $1,599 · 2022: $1,181 · 2023: $1,085 · 2024: $1,338 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500 · Entertainment: $14.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.50 |
| Entertainment | $14.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,092.77 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,059.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $930.17 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $918.03 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $846.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $704.11 | 2019-2022 | |
| Pfizer INC. | $677.67 | 2019-2025 | |
| Abbvie INC. | $543.36 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $532.99 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $426.11 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $342.41 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $258.64 | 2019-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.88 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $166.04 | 2019-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $145.68 | 2023-2024 | Quviviq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.